Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics

Magenta Therapeutics, Inc. (MGTA): $1.21

-0.04 (-3.20%)

POWR Rating

Component Grades













MGTA Stock Price Chart Interactive Chart >

Price chart for MGTA

MGTA Price/Volume Stats

Current price $1.21 52-week high $10.84
Prev. close $1.25 52-week low $0.92
Day low $1.21 Volume 65,100
Day high $1.30 Avg. volume 333,557
50-day MA $1.34 Dividend yield N/A
200-day MA $4.04 Market Cap 71.15M

Magenta Therapeutics, Inc. (MGTA) Company Bio

Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.

MGTA Latest News Stream

Event/Time News Detail
Loading, please wait...

MGTA Latest Social Stream

Loading social stream, please wait...

View Full MGTA Social Stream

Latest MGTA News From Around the Web

Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...

Yahoo | February 7, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o

Yahoo | January 18, 2022

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

CAMBRIDGE, Mass., January 10, 2022--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today highlighted progress across its portfolio of targeted conditioning and stem cell mobilization programs and set out its milestone expectations for both clinical and preclinical data in 2022. These updates will also be discussed during a webcast presentation at the 40th Annual

Yahoo | January 10, 2022

Magenta rises 6% on Goldman Sachs upgrade with $8 target price (NASDAQ:MGTA)

Goldman Sachs analyst Madhu Kumar upgraded Magenta Therapeutics (MGTA) to Buy from Neutral with a price target ((PT)) of $8, up from $7. Shares up 6% premarket at $4.73

Seeking Alpha | January 6, 2022

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference

CAMBRIDGE, Mass., January 05, 2022--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences:

Yahoo | January 5, 2022

Read More 'MGTA' Stories Here

MGTA Price Returns

1-mo N/A
3-mo -58.28%
6-mo -72.69%
1-year -88.32%
3-year -91.80%
5-year N/A
YTD -72.69%
2021 -43.49%
2020 -48.28%
2019 165.96%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4855 seconds.